A Saudi-based distributor of medical devices with decades of experience has been has been appointed to distribute EndoBarrier across several Middle East countries on a renewable three-year contract with minimum purchase requirements. The broker believes the strategy is a sound one in a large self-pay market.
Target $1.85 (was $1.90). The broker notes the French Government will pay for a clinical study of the company’s EndoBarrier treatment. This is the second study they have paid for, with the new work not so much about efficacy, but rather an investigation into potential price and reimbursement levels based on patient outcomes versus traditional treatment.